<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539769</url>
  </required_header>
  <id_info>
    <org_study_id>KNUCH 2017-07-011</org_study_id>
    <nct_id>NCT04539769</nct_id>
  </id_info>
  <brief_title>Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes</brief_title>
  <official_title>Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University Chilgok Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyungpook National University Chilgok Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a rapidly growing interest in metabolic surgery for the treatment of type 2&#xD;
      diabetes. However, its efficacy in the non-morbidly population is not clear yet and the&#xD;
      underlying mechanism remains elusive.&#xD;
&#xD;
      Meanwhile, the incidence of early gastric cancer (EGC) in Korea has gradually increased, the&#xD;
      long-term quality of life of the patients with EGC has become an important issue. Since the&#xD;
      reconstruction methods after gastric cancer surgery are similar to that of metabolic surgery,&#xD;
      some surgeons have attempted to modify the reconstruction methods after standard radical&#xD;
      gastrectomy to achieve better glycemic control in gastric cancer patients with type 2&#xD;
      diabetes.&#xD;
&#xD;
      The present study aimed to investigate the changes in glucose metabolism and incretin hormone&#xD;
      responses following different types of reconstruction after distal gastrectomy in&#xD;
      non-morbidly obese gastric cancer patients with type 2 diabetes. This is a non-randomized,&#xD;
      prospective, single-center, phase II pilot study.&#xD;
&#xD;
      Patients diagnosed with stage I gastric cancer and type 2 diabetes are eligible for the&#xD;
      present study. Patients who will undergo laparoscopic distal gastrectomy for cancer located&#xD;
      at the lower two-thirds of the stomach will only be included. The reconstruction method will&#xD;
      be selected among conventional Billroth I, long-limb Billroth II (with 100 cm-long&#xD;
      biliopancreatic limb), or long-limb Roux-en-Y (with 100 cm-long Roux limb) reconstruction&#xD;
      methods according to the surgeon's preference as well as the size of the remnant stomach. All&#xD;
      the patients are subjected to a 75g-oral glucose tolerance test (OGTT) preoperatively, and at&#xD;
      5 days, 3 months, 6 months postoperatively and serum glucose, as well as incretin hormones,&#xD;
      will be serially measured.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetes remission rate</measure>
    <time_frame>at 6 months after surgery</time_frame>
    <description>the rate of patients achieving HbA1c &lt; 6.5% without antidiabetic medications</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Billroth I reconstruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BII group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Billroth II reconstruction with 100-cm long biliopancreatic limb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RY group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roux-en-Y reconstruction with 100-cm long Roux limb</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional BI</intervention_name>
    <description>After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.</description>
    <arm_group_label>BI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>long-limb BII</intervention_name>
    <description>After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.</description>
    <arm_group_label>BII group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>long-limb RY group</intervention_name>
    <description>After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.</description>
    <arm_group_label>RY group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with type 2 diabetes as well as pathologically proven gastric&#xD;
             cancer of clinical stage I according to the AJCC 7th edition&#xD;
&#xD;
          -  Those who are expected to undergo laparoscopic distal gastrectomy&#xD;
&#xD;
          -  Body mass index &lt; 30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. baseline fasting C-peptide level &lt; 1.0 ng/dL (who had the possibility of type 1&#xD;
             diabetes)&#xD;
&#xD;
          2. previous radiotherapy or surgery at upper abdomen other than laparoscopic&#xD;
             cholecystectomy&#xD;
&#xD;
          3. other malignancies in recent 5 years&#xD;
&#xD;
          4. vulnerable patients (pregnant women, those with cognitive impairment, etc)&#xD;
&#xD;
          5. ECOG-PS â‰¥ 2&#xD;
&#xD;
          6. participating in other clinical trials within 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University Chilgok Hospital</investigator_affiliation>
    <investigator_full_name>Ji Yeon Park</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

